Sustainability of vaginal estrogens for genitourinary syndrome of menopause - a systematic review.

Weidlinger, S; Schmutz, C; Janka, H; Gruetter, C; Stute, P (2021). Sustainability of vaginal estrogens for genitourinary syndrome of menopause - a systematic review. Climacteric, 24(6), pp. 551-559. Informa Healthcare 10.1080/13697137.2021.1891218

	Text Weidlinger_Climacteric_2021_epub.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (1MB)
Preview	Text (Search strategies) Weidlinger_Climacteric_2021_supplmat.pdf - Supplemental Material Available under License Publisher holds Copyright. Download (181kB) | Preview

Genitourinary syndrome of menopause (GSM) is a highly prevalent, not self-limiting condition displaying a major negative impact on sexual function and emotional well-being. Various non-hormonal and hormonal treatment options are available. Many women consider GSM treatment to be a short-term interval cure rather than a long-term or lifelong treatment. The aim of this systematic literature search was to assess the sustainability of vaginal estrogens for GSM treatment after treatment cessation. We found that objective GSM signs mostly deteriorated within approximately 4 weeks after vaginal estrogen treatment cessation, while vaginal estrogens had a more sustainable impact on subjective GSM symptoms up to 3-6 months. However, overall, scientific evidence on sustainability of vaginal estrogens was low. Thus, GSM treatment should not be considered a short-term interval cure but long-term therapy. Further studies in an internationally harmonized setting (Core Outcomes in Menopause [COMMA]) are needed.

Interest & Impact

Downloads

83 since deposited on 07 Jan 2022
32 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item